AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03772899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbial Transplantation
Description: All patients in this trial will receive FMT at least one week prior to treatment with approved immunotherapy (either pembrolizumab or nivolumab). Samples for FMT are sourced at and by the microbiology group under the supervision of Dr. Silverman at St Joseph's Hospital. Donor screening procedures are described in appendix 4. Transplant will be from one single donor for all participants unless Dr. Silverman's lab considers the need for more than one donor based on availability of donors. There will be no mixture of donor samples.~Donor samples are manufactured into capsules according to Kao et al, 2017.
Study NCT00644423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fatty Acid
Description: One capsule three times per day x 1 day (325mg EPA/225mg docosahexaenoic acid (DHA) tid) Two capsules three times per day x 1 day (650mg EPA/450mg DHA tid) Three capsules three times per day thereafter (975mg EPA/675mg DHA tid)
Study NCT00644423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT00781768 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard PO (Zofran + Dexamethason)
Description: Dexamethasone 10 mg (dose blinded) in 50 ml D5W IVPB over 15 minutes daily + ondansetron 8mg PO q 8 hours - repeated qd of the preparative regimen and for 1 day after completion. A placebo capsule will be given daily on each day of the preparative regimen plus 3 days after. Antiemetic therapy will start a minimum of 30 minutes prior to and continued for 24 hours after completion of the preparative regimen.
Study NCT00781768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant (MK-869) + Standard PO
Description: Dexamethasone 7.5 mg (dose blinded) in 50 ml D5W IVPB over 15 min daily + ondansetron 8mg PO q 8 hours - repeated QD of the preparative regimen and for 1 day after completion. Aprepitant 125mg PO \[blinded\] will be given a minimum of 30 minutes prior to the preparative regimen on day 1. MK-Aprepitant 80mg PO \[blinded\] will be given will be given approximately 24 hours later starting on day 2 then each day of the preparative regimen plus 3 days after. Antiemetic therapy will start a minimum of 30 minutes prior to and continued for 24 hours after completion of the preparative regimen.
Study NCT01395797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIO
Description: 0, 15, and 45 mg per day.
Study NCT01395797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PIO
Description: 0, 15, and 45 mg per day.
Study NCT01395797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01500590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system blockers
Description: ramipril 2.5mg to 10mg once daily if patient experience cough, we will use irbesartan 150 mg to 300mg once daily
Study NCT01500590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-renin angiotensin system blockers
Description: amlodipine 2.5 to 10 mg once daily nifedipine retard 20mg to 40mg twice daily indapamide 2.5mg once daily metoprolol 25mg to 100mg daily methyldopa 125 mg to 500mg twice daily
Study NCT02025686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen
Description: Subjects will breathe oxygen (FIO2 = 1.0) at 2.4 ATA in a hyperbaric chamber after the tonic heat stimulations. The duration of oxygen exposure is 90 min.
Study NCT02025686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal ambient conditions
Description: Normal ambient conditions (1 ATA, FIO2 = 0.21)
Study NCT03744910 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Clazakizumab
Description: Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6
Study NCT03744910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic saline solution
Description: Normal saline
Study NCT00500617 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Corus CAD (ASGES)
Description: Age/Sex/Gene Expression Score - ASGES
Study NCT01647789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFG920
Study NCT03744312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-ER176
Description: 11C-ER176 sticks to parts of the brain where there is inflammation. Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease. The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease.
Study NCT00417261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXT914
Study NCT00417261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AXT914
Study NCT03284047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Participants will be randomized to one of three botulinum toxin type A doses.
Study NCT03744312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 11C-ER176
Description: 11C-ER176 sticks to parts of the brain where there is inflammation. Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease. The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease.
Study NCT03744312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetaben
Description: Florbetaben sticks to amyloid plaques, which are in the brain in Alzheimer's disease.
Study NCT03744312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Florbetaben
Description: Florbetaben sticks to amyloid plaques, which are in the brain in Alzheimer's disease.
Study NCT01893463 — intervention group
Intervention type: DEVICE
Intervention: iTClamp50
Study NCT02686372 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCR-T
Description: Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
Study NCT02686372 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: No intervention and TCR-T (at crossover)
Description: Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
Study NCT04432935 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine Lactoferrin
Description: Lactoferrin is a nutritional supplement which was first discovered in bovine milk which was later isolated in human milk as the second most abundant protein; with high levels found in colostrum. The use of bovine Lactoferrin in children is generally recognized as safe by the US Food and Drug Administration.
Study NCT04432935 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Glucon D
Description: This group will be given 100mg Glucon-D (99.4% glucose) which will be similar in shape, color to the bLF.
Study NCT03096834 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG334 (70 mg) Pre-Filled Syringe (PFS)
Description: Two injections of AMG 334 70 mg (equaling 140 mg total dose) will be administered via subcutaneous injection
Study NCT03096834 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pre-Filled Syringe (PFS)
Description: Subcutaneous injection of matching placebo
Study NCT00246519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: atenolol 50 or 100 mg hydrochlorothiazide 12.5 or 25 mg
Study NCT00246519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: atenolol 50 mg, then 100 mg if BP \< 120/70, then add HCTZ 12.5 mg if BP \< 120/70, then HCTZ 25 mg if BP \< 120/70
Study NCT02374697 — intervention group
Intervention type: DEVICE
Intervention: During tele-expertise
Study NCT00002649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given IV
Study NCT00002649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC or IV
Study NCT00002649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00002649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00002649 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT00002649 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo autologous peripheral blood stem cell transplant
Study NCT00002649 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support
Description: Undergo bone marrow ablation with stem cell support
Study NCT04017221 — intervention group
Intervention type: DRUG
Intervention: Sodium-glucose cotransporter 2 (SGLT2) inhibitors
Description: Current exposure to SGLT2 will be defined as a prescription for a SGLT2 inhibitor (canagliflozin, dapagliflozin, empagliflozin) alone or in combination with other antidiabetic drugs, excluding DPP-4 inhibitors and insulin.
Study NCT04017221 — intervention group
Intervention type: DRUG
Intervention: Dipeptidyl peptidase-4 (DPP-4) inhibitors
Description: Current exposure to DPP-4 will be defined as a prescription for a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) alone or in combination with other antidiabetic drugs, excluding SGLT2 inhibitors and insulin.
Study NCT04017221 — intervention group
Intervention type: DRUG
Intervention: Other treatment combinations
Description: Current exposure to other treatment combinations will be defined as a prescription of other antidiabetic drugs (metformin, sulfonylureas, thiazolidinediones, GLP-1 receptor agonists, alpha-glucosidase inhibitors, meglitinides, insulin, or combinations of these drugs), current use of insulin (alone or combination with other antidiabetic drugs), and non-current use of antidiabetic drugs.
Study NCT04045535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Program
Description: Usual Care and a nurse-led physical activity program once a week for 8 weeks. Each session last for 60 minutes, 15 for warming-up and 45 for different exercises.
Study NCT04045535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual clinical care based on current clinical practice guidelines.
Study NCT04045535 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual clinical care based on current clinical practice guidelines.
Study NCT03338777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Suicide plus immunogene therapy
Description: 1. Intra and peritumoral infiltrates with multiple injections of 0.1 ml/cm2 or 0.2 ml/cm3 of lipoplexes bearing the HSVtk suicide gene (1: 1; 1 mg/ml, according to tumor size), co-administered with GCV (12.5 mg/ml). Patients start with a minimum of 0.5 ml and at the 3rd week, the maximum dose is scaled according to the tumor size up to 2 ml maximum.~2. Treated simultaneously with a subcutaneous vaccine produced with:~   * Formolized allogeneic tumor extracts and,~  * Lipoplexes carrying hIL-2 and hGM-CSF genes (0.5 mg each).
Study NCT00717574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane group
Description: Addition of 60% nitrous oxide for 20 minutes duration, then back to 1:1 oxygen/air mixture.
Study NCT00717574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol group
Description: Addition of 60% nitrous oxide for 20 minutes duration, then back to 1:1 oxygen/air mixture.
Study NCT00982293 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resonator device
Description: Low level electromagnetic fields for whole body immersion, 3 times weekly for 13 weeks (39) sessions of approximately 11/2 hours each.
Study NCT00982293 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Resonator device - sham
Description: Treatment, 3 times weekly for 13 weeks (39) sessions - device will not be on
Study NCT00704015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Description: Nurses, specifically trained for smoking cession program, contacted the patients at the orthopedic wards and initiated the intervention (stop smoking) within 1-2 days after acute hospitalization. The intervention included one or two personal meetings and weekly phone contacts during 6 weeks with a trained nurse. A phone number to a non-smoking hotline was provided for all patients. The patients were continuously encouraged not to smoke and free nicotine substitution (Nicorette®) was offered those who needed it. No other drug therapy was used.
Study NCT03633396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imsidolimab
Description: Administered by subcutaneous injection once a month
Study NCT03633396 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection once a month
Study NCT03471351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenalisib
Description: Tenalisib, BID, orally and Pembrolizumab 200 mg IV Q3W
Study NCT03471351 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Tenalisib, BID, orally and Pembrolizumab 200 mg IV Q3W
Study NCT01276938 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 21 Gy radiation
Description: 21 Gy radiation using electrons produced with mobile linear accelerator (energies ranging from 4 to 10 MeV)
Study NCT01276938 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18 Gy radiation
Description: 18 Gy radiation using electrons produced with mobile linear accelerator (energies ranging from 4 to 10 MeV)
Study NCT04369482 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alcon Clareon
Description: Implantation of an intraocular lens Alcon Clareon
Study NCT04369482 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hoya Vivinex
Description: Implantation of an intraocular lens Hoya Vivinex
Study NCT01408615 — intervention group
Intervention type: DRUG
Intervention: corifollitropin alfa
Description: 100 or 150 microgram single subcutaneous injection
Study NCT03643393 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: perineal rectosigmoidectomy
Description: In an Altemeier perineal rectosigmoidectomy, a full-thickness circumferential incision is made in the prolapsed rectum about 1-2 cm from the dentate line (see the image below). The hernia sac is entered, and the prolapse is delivered. The mesentery of the prolapsed bowel is serially ligated until no further redundant bowel can be pulled down. The bowel is transected and either hand-sewn to the distal anal canal or stapled with a circular stapler. Before anastomosis, some surgeons plicate the levator ani muscles anteriorly, which may help improve continence.
Study NCT01690052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cevimeline
Description: Cevimlenine Vs Pilocarpine, cross over design. Two sequences were evaluated cevimeline first, then pilocarpine and pilocarpine first, then cevimeline. Each sequence was evaluated for 4 weeks with one week washout period in between both sequences. 15 patients were randomly assigned to a specific sequence by a research pharmacist independent from the study authors. The patients received 30mg of cevimeline three times a day and pilocarpine 5mg three times a day.
Study NCT01690052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pilocarpine
Description: Cevimlenine Vs Pilocarpine, cross over design, 4 weeks, one week wash out
Study NCT02685319 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: muscle biopsy
Description: a muscle sample will be taken from the mid-thigh (Vastus Lateralis) and analyzed
Study NCT02660177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizole
Description: metamizole IV administration
Study NCT00882440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium
Description: losartan oral capsule (10, 25, 50, 100 or 150 mg) once daily for 8 weeks
Study NCT01313247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: 1000 mg 4 times daily
Study NCT01313247 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablets
Description: Placebo pills eqv paracetamol are given 2 tablets 4 times daily instead of paracetamol
Study NCT01048554 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Temozolomide
Description: Temozolomide 75mg/m2 for six continuous weeks
Study NCT00882440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule to losartan
Study NCT00882440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Enalapril 20 mg oral tablet taken once daily for 8 weeks
Study NCT00915954 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Oral Glucose Tolerance Test
Description: Participants will have their blood drawn for a baseline value and then will be asked to drink a beverage with 75 grams of sugar. Blood will then be drawn every 30 minutes for 2 hours.
Study NCT00915954 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous administration of recombinant human IGF-1
Description: Participants will receive a subcutaneous injection of recombinant human IGF-1 followed by a series of blood draws.
Study NCT00915954 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive a subcutaneous injection of saline followed by a series of blood draws.
Study NCT02474797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diaphragmatic ultrasonography
Description: Daily Measure of Diaphragmatic Thickening Fraction (DTF) will be performed by a trained physiotherapist. Physiotherapist (A. LE NEINDRE). The patient will be then instructed to perform breathing to total lung capacity and then to exhale to residual volume, when it is possible (awaken patient). Awakening status will be recorded. Mechanically ventilated patients will be evaluated in Pressure Support (PS) mode (during daily PS mode research for patients with Controlled Ventilation), with the lower PS level tolerated. PS level will be recorded.~Thickening fraction (TF) measure is performed in B-mode using the following formula: TF (%) = \[(end-inspiration thickness - end-expiration thickness)/(end-expiration thickness) x 100\]. Diaphragmatic dysfunction is defined like a DTF \< 20% (7).
Study NCT03388034 — intervention group
Intervention type: PROCEDURE
Intervention: Nasopharyngeal sampling
Description: A nasopharyngeal sample collected from each nostril by swabbing
Study NCT01048554 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: Bevacizumab 10mg/kg every 2 weeks without interruption
Study NCT03388034 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Sampling
Description: Blood sample by the tip of a finger (fingerprick)
Study NCT02909530 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNB with EZ Shot 3Plus first
Description: Both needles (EZ Shot 3Plus 19G and EZ Shot 2 19G) will be used for endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) in each patient following a predetermined random order which needle is used to pass through the tumor first.
Study NCT03177902 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: Newly diagnosed breast cancer patients undergoing at least four cycles of chemotherapy.
Study NCT00387881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sumatriptan succinate / naproxen sodium
Description: sumatriptan 85mg / naproxen sodium 500mg
Study NCT00387881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match Treximet tablets
Study NCT05621330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL0911
Description: The study in a 2:1 randomization ratio(144 subjects to QL0911). Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
Study NCT05621330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: The study in a 2:1 randomization ratio(72 subjects to Placebo ). Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
Study NCT02760459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT02760459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline solution
Study NCT04649541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MRX-8
Description: novel semi-synthetic polymyxin B analog.
Study NCT04649541 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5% dextrose in water
Study NCT03156101 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BinD19
Description: Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR-ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.
Study NCT03429335 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching session
Description: The cardiology nurse (RN) will have an hour long one-on-one teaching session prior to their pediatric cardiology clinic visit. The RN will go over the youth's cardiac history including the chronic heart disease diagnoses, names and dates of cardiac surgical procedures and cardiac catheterizations, and current cardiac medications and doses. She will also discuss transitioning from pediatric to adult care and healthy lifestyle choices.